60 related articles for article (PubMed ID: 10086699)
1. FDG and L-[1-11C]-tyrosine imaging of soft-tissue tumors before and after therapy.
Kole AC; Plaat BE; Hoekstra HJ; Vaalburg W; Molenaar WM
J Nucl Med; 1999 Mar; 40(3):381-6. PubMed ID: 10086699
[TBL] [Abstract][Full Text] [Related]
2. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer.
van Ginkel RJ; Kole AC; Nieweg OE; Molenaar WM; Pruim J; Koops HS; Vaalburg W; Hoekstra HJ
J Nucl Med; 1999 Feb; 40(2):262-7. PubMed ID: 10025833
[TBL] [Abstract][Full Text] [Related]
3. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
[TBL] [Abstract][Full Text] [Related]
4. Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity.
Jager PL; Plaat BE; de Vries EG; Molenaar WM; Vaalburg W; Piers DA; Hoekstra HJ
Clin Cancer Res; 2000 Jun; 6(6):2252-9. PubMed ID: 10873075
[TBL] [Abstract][Full Text] [Related]
5. Protein synthesis rate measured with L-[1-11C]tyrosine positron emission tomography correlates with mitotic activity and MIB-1 antibody-detected proliferation in human soft tissue sarcomas.
Plaat B; Kole A; Mastik M; Hoekstra H; Molenaar W; Vaalburg W
Eur J Nucl Med; 1999 Apr; 26(4):328-32. PubMed ID: 10199937
[TBL] [Abstract][Full Text] [Related]
6. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
[TBL] [Abstract][Full Text] [Related]
7. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine.
Kaschten B; Stevenaert A; Sadzot B; Deprez M; Degueldre C; Del Fiore G; Luxen A; Reznik M
J Nucl Med; 1998 May; 39(5):778-85. PubMed ID: 9591574
[TBL] [Abstract][Full Text] [Related]
8. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant.
Spence AM; Muzi M; Graham MM; O'Sullivan F; Krohn KA; Link JM; Lewellen TK; Lewellen B; Freeman SD; Berger MS; Ojemann GA
J Nucl Med; 1998 Mar; 39(3):440-8. PubMed ID: 9529289
[TBL] [Abstract][Full Text] [Related]
9. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma.
van Ginkel RJ; Hoekstra HJ; Pruim J; Nieweg OE; Molenaar WM; Paans AM; Willemsen AT; Vaalburg W; Koops HS
J Nucl Med; 1996 Jun; 37(6):984-90. PubMed ID: 8683328
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET.
Jones DN; McCowage GB; Sostman HD; Brizel DM; Layfield L; Charles HC; Dewhirst MW; Prescott DM; Friedman HS; Harrelson JM; Scully SP; Coleman RE
J Nucl Med; 1996 Sep; 37(9):1438-44. PubMed ID: 8790188
[TBL] [Abstract][Full Text] [Related]
11. L-1-11C-tyrosine PET in patients with laryngeal carcinomas: comparison of standardized uptake value and protein synthesis rate.
de Boer JR; Pruim J; van der Laan BF; Que TH; Willemsen AT; Albers FW; Vaalburg W
J Nucl Med; 2003 Mar; 44(3):341-6. PubMed ID: 12620998
[TBL] [Abstract][Full Text] [Related]
12. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas.
Bredella MA; Caputo GR; Steinbach LS
AJR Am J Roentgenol; 2002 Nov; 179(5):1145-50. PubMed ID: 12388489
[TBL] [Abstract][Full Text] [Related]
13. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
[TBL] [Abstract][Full Text] [Related]
14. FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma.
Vernon CB; Eary JF; Rubin BP; Conrad EU; Schuetze S
Skeletal Radiol; 2003 Mar; 32(3):139-42. PubMed ID: 12605277
[TBL] [Abstract][Full Text] [Related]
15. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy.
Goldman S; Levivier M; Pirotte B; Brucher JM; Wikler D; Damhaut P; Dethy S; Brotchi J; Hildebrand J
J Nucl Med; 1997 Sep; 38(9):1459-62. PubMed ID: 9293808
[TBL] [Abstract][Full Text] [Related]
16. PET with L-[1-carbon-11]-tyrosine to visualize tumors and measure protein synthesis rates.
Kole AC; Pruim J; Nieweg OE; van Ginkel RJ; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
J Nucl Med; 1997 Feb; 38(2):191-5. PubMed ID: 9025733
[TBL] [Abstract][Full Text] [Related]
17. Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors.
Kole AC; Nieweg OE; Hoekstra HJ; van Horn JR; Koops HS; Vaalburg W
J Nucl Med; 1998 May; 39(5):810-5. PubMed ID: 9591581
[TBL] [Abstract][Full Text] [Related]
18. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma.
Eary JF; Conrad EU; Bruckner JD; Folpe A; Hunt KJ; Mankoff DA; Howlett AT
Clin Cancer Res; 1998 May; 4(5):1215-20. PubMed ID: 9607579
[TBL] [Abstract][Full Text] [Related]
19. In vivo protein synthesis rate determination in primary or recurrent brain tumors using L-[1-11C]-tyrosine and PET.
Willemsen AT; van Waarde A; Paans AM; Pruim J; Luurtsema G; Go KG; Vaalburg W
J Nucl Med; 1995 Mar; 36(3):411-9. PubMed ID: 7884503
[TBL] [Abstract][Full Text] [Related]
20. Carbon-11-thymidine and FDG to measure therapy response.
Shields AF; Mankoff DA; Link JM; Graham MM; Eary JF; Kozawa SM; Zheng M; Lewellen B; Lewellen TK; Grierson JR; Krohn KA
J Nucl Med; 1998 Oct; 39(10):1757-62. PubMed ID: 9776283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
